These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Clinical characteristics and treatment outcomes of pleural effusions in patients with nontuberculous mycobacterial disease. Park S; Jo KW; Lee SD; Kim WS; Shim TS Respir Med; 2017 Dec; 133():36-41. PubMed ID: 29173447 [TBL] [Abstract][Full Text] [Related]
27. Epidemiology of Pulmonary Nontuberculous Mycobacterial Sputum Positivity in Patients with Cystic Fibrosis in the United States, 2010-2014. Adjemian J; Olivier KN; Prevots DR Ann Am Thorac Soc; 2018 Jul; 15(7):817-826. PubMed ID: 29897781 [TBL] [Abstract][Full Text] [Related]
28. A narrative review of nontuberculous mycobacterial pulmonary disease: microbiology, epidemiology, diagnosis, and management challenges. Hamed KA; Tillotson G Expert Rev Respir Med; 2023; 17(11):973-988. PubMed ID: 37962332 [TBL] [Abstract][Full Text] [Related]
29. Nontuberculous mycobacterial pulmonary diseases in immunocompetent patients. Koh WJ; Kwon OJ; Lee KS Korean J Radiol; 2002; 3(3):145-57. PubMed ID: 12271159 [TBL] [Abstract][Full Text] [Related]
30. Microbiome Diversity in Sputum of Nontuberculous Mycobacteria Infected Women with a History of Breast Cancer. Philley JV; Kannan A; Olusola P; McGaha P; Singh KP; Samten B; Griffith DE; Dasgupta S Cell Physiol Biochem; 2019; 52(2):263-279. PubMed ID: 30816674 [TBL] [Abstract][Full Text] [Related]
31. Global trends of pulmonary infections with nontuberculous mycobacteria: a systematic review. Dahl VN; Mølhave M; Fløe A; van Ingen J; Schön T; Lillebaek T; Andersen AB; Wejse C Int J Infect Dis; 2022 Dec; 125():120-131. PubMed ID: 36244600 [TBL] [Abstract][Full Text] [Related]
32. Implication of species change of Nontuberculous Mycobacteria during or after treatment. Lee JS; Lee JH; Yoon SH; Kim TS; Seong MW; Han SK; Yim JJ BMC Pulm Med; 2017 Dec; 17(1):213. PubMed ID: 29262802 [TBL] [Abstract][Full Text] [Related]
33. Recent advances in molecular diagnostics and understanding mechanisms of drug resistance in nontuberculous mycobacterial diseases. Huh HJ; Kim SY; Jhun BW; Shin SJ; Koh WJ Infect Genet Evol; 2019 Aug; 72():169-182. PubMed ID: 30315892 [TBL] [Abstract][Full Text] [Related]
36. Summary for Clinicians: 2020 Clinical Practice Guideline Summary for the Treatment of Nontuberculous Mycobacterial Pulmonary Disease. Kurz SG; Zha BS; Herman DD; Holt MR; Daley CL; Ruminjo JK; Thomson CC Ann Am Thorac Soc; 2020 Sep; 17(9):1033-1039. PubMed ID: 32870060 [No Abstract] [Full Text] [Related]
38. Global Epidemiology of Nontuberculous Mycobacterial Pulmonary Disease: A Review. Prevots DR; Marshall JE; Wagner D; Morimoto K Clin Chest Med; 2023 Dec; 44(4):675-721. PubMed ID: 37890910 [TBL] [Abstract][Full Text] [Related]
39. Nontuberculous Mycobacterial Disease Epidemiology: You Can See the Stars and Still Not See the Light. Griffith DE; Marras TK Clin Infect Dis; 2021 Jul; 73(2):e327-e329. PubMed ID: 32756945 [No Abstract] [Full Text] [Related]
40. In Vitro Efficacy of Free and Nanoparticle Formulations of Gallium(III) meso-Tetraphenylporphyrine against Mycobacterium avium and Mycobacterium abscessus and Gallium Biodistribution in Mice. Choi SR; Britigan BE; Switzer B; Hoke T; Moran D; Narayanasamy P Mol Pharm; 2018 Mar; 15(3):1215-1225. PubMed ID: 29421865 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]